Fig. 2.
In vitro characterization of chimeric activator variants. (A) Fusion proteins were analyzed by SDS/PAGE to determine purity, presence of full-length protein (72 kDa), potential degradation products, and release of N-linked carbohydrate chains on treatment with (+) or without (–) PNGase F enzyme. PNGase F runs at 32 kDa. (B) Results of in vitro kinetic analysis of interaction between EPO-R and unfused EPO, EPOR150A, 10F7-EPO, or 10F7-EPOR150A. (C) In vitro proliferation of EPO-R–positive MCF-7 and BT-549 cells vs. EPO-R–negative HeLa cells after treatment with 10F7-EPO or 10F7-EPOR150A. Graphs display mean ± SEM (n = 3).